Edmonston T B, Cuesta K H, Burkholder S, Barusevicius A, Rose D, Kovatich A J, Boman B, Fry R, Fishel R, Palazzo J P
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA 19107, USA.
Hum Pathol. 2000 Dec;31(12):1506-14. doi: 10.1053/hupa.2000.20383.
Molecular analysis of hereditary nonpolyposis colorectal carcinomas (HNPCC) has identified DNA mismatch repair deficiencies with resulting microsatellite instability (MSI) as a pathway of carcinogenesis that appears to be relevant for prognosis, treatment, and possibly prevention. In this study, expression of cell cycle proteins and other known prognostic markers is correlated with the microsatellite status of colorectal cancers (CRC). One hundred consecutive cases from the CRC Registry at Thomas Jefferson University were analyzed for MSI. Immunohistochemistry was performed for the mismatch repair proteins hMLH1 and hMSH2, tumor suppressor p53, apoptosis inhibitor bcl-2, cell cycle proteins p21(WAF1/CIP1), and p27 and the proliferation markers Ki-67 and topoisomerase II. High MSI (MSI-H) is significantly correlated with loss of either hMLH1 or hMSH2, presence of bcl-2, and absence of p53. p21(WAF1/CIP1) is positive in all tumors with MSI-H. Previous findings of a lower proliferation rate were confirmed with a topoisomerase II stain. Microsatellite stable (MSS) tumors generally express both MSH2 and MLH1. Other highly significant differences are positive p53 in 56% of MSS cases and negative bcl-2 in 98% of MSS cases. p27 expression is found in approximately 50% of all CRCs irrespective of the microsatellite status. MSI-H tumors follow the mutator pathway, with loss of expression of one mismatch repair protein, wild-type p53, lower proliferation, and positivity for p21(WAF1/CIP1). MSS tumors follow the suppressor pathway, characterized by p53 overexpression, higher proliferation, and absence of bcl-2 expression; p21(WAF1/CIP1) expression can be variable. These data provide a molecular basis for the clinical observation that patients with HNPCC appear to have a more favorable prognosis. HUM PATHOL 31:1506-1514.
遗传性非息肉病性结直肠癌(HNPCC)的分子分析已确定,DNA错配修复缺陷导致微卫星不稳定性(MSI)是一种致癌途径,这似乎与预后、治疗乃至预防都相关。在本研究中,细胞周期蛋白和其他已知预后标志物的表达与结直肠癌(CRC)的微卫星状态相关。对托马斯杰斐逊大学CRC登记处的100例连续病例进行了MSI分析。对错配修复蛋白hMLH1和hMSH2、肿瘤抑制因子p53、凋亡抑制剂bcl-2、细胞周期蛋白p21(WAF1/CIP1)和p27以及增殖标志物Ki-67和拓扑异构酶II进行了免疫组织化学检测。高MSI(MSI-H)与hMLH1或hMSH2的缺失、bcl-2的存在以及p53的缺失显著相关。p21(WAF1/CIP1)在所有MSI-H肿瘤中均呈阳性。拓扑异构酶II染色证实了先前关于较低增殖率的研究结果。微卫星稳定(MSS)肿瘤通常同时表达MSH2和MLH1。其他高度显著的差异包括,56%的MSS病例中p53呈阳性,98%的MSS病例中bcl-2呈阴性。无论微卫星状态如何,约50%的所有CRC中都可检测到p27表达。MSI-H肿瘤遵循突变途径,表现为一种错配修复蛋白表达缺失、野生型p53、较低增殖以及p21(WAF1/CIP1)呈阳性。MSS肿瘤遵循抑制途径,其特征为p53过表达、较高增殖以及bcl-2表达缺失;p21(WAF1/CIP1)表达可能存在差异。这些数据为HNPCC患者似乎具有更良好预后这一临床观察提供了分子基础。《人类病理学》31:1506 - 1514。